tradingkey.logo

BioLife Solutions Inc

BLFS
查看详细走势图
24.900USD
-0.510-2.01%
收盘 12/26, 16:00美东报价延迟15分钟
1.19B总市值
亏损市盈率 TTM

BioLife Solutions Inc

24.900
-0.510-2.01%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.01%

5天

-0.68%

1月

-6.67%

6月

+15.92%

今年开始到现在

-4.08%

1年

-7.88%

查看详细走势图

TradingKey BioLife Solutions Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

BioLife Solutions Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名17/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价32.10。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

BioLife Solutions Inc评分

相关信息

行业排名
17 / 207
全市场排名
89 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 10 位分析师
买入
评级
32.100
目标均价
+28.66%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

BioLife Solutions Inc亮点

亮点风险
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
业绩增长期
公司处于发展阶段,最新年度总收入82.25M美元
估值低估
公司最新PE估值-448.89,处于3年历史低位
机构减仓
最新机构持股49.86M股,环比减少1.47%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值80.95K

BioLife Solutions Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

BioLife Solutions Inc简介

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
公司代码BLFS
公司BioLife Solutions Inc
CEODe Greef (Roderick)
网址https://www.biolifesolutions.com/

常见问题

BioLife Solutions Inc(BLFS)的当前股价是多少?

BioLife Solutions Inc(BLFS)的当前股价是 24.900。

BioLife Solutions Inc的股票代码是什么?

BioLife Solutions Inc的股票代码是BLFS。

BioLife Solutions Inc股票的52周最高点是多少?

BioLife Solutions Inc股票的52周最高点是29.620。

BioLife Solutions Inc股票的52周最低点是多少?

BioLife Solutions Inc股票的52周最低点是19.100。

BioLife Solutions Inc的市值是多少?

BioLife Solutions Inc的市值是1.19B。

BioLife Solutions Inc的净利润是多少?

BioLife Solutions Inc的净利润为-20.18M。

现在BioLife Solutions Inc(BLFS)的股票是买入、持有还是卖出?

根据分析师评级,BioLife Solutions Inc(BLFS)的总体评级为买入,目标价格为32.100。

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是多少

BioLife Solutions Inc(BLFS)股票的每股收益(EPS TTM)是-0.055。
KeyAI